Skip to main content
See every side of every news story
Published loading...Updated

Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval

UNITED STATES, AUG 7 – Orforglipron led to 12% average weight loss in an 18-month trial of over 3,000 adults with obesity, with 60% losing at least 10%, company data show.

  • On August 7, 2025, Eli Lilly reported successful primary outcomes from its global Phase 3 ATTAIN-1 study evaluating orforglipron, an oral medication for obesity.
  • The 72-week trial involved 3,127 adults with obesity or overweight and weight-related conditions but no diabetes, aiming to surpass placebo in body weight reduction.
  • Participants on the highest 36 mg dose lost an average of 12.4% body weight , and 59.6% lost at least 10%, with side effects similar to injectable GLP-1 drugs.
  • Eli Lilly aims to file for regulatory approval of orforglipron by the end of the year and is investing over $600 million in production capacity to support anticipated demand for its worldwide introduction in response to critical health challenges.
  • The results position orforglipron as a convenient once-daily oral alternative for obesity treatment, with detailed data expected at a September conference and possible market entry next year.
Insights by Ground AI
Does this summary seem wrong?
Podcasts & Opinions

73 Articles

A new group of active ingredients helps with diabetes and obesity. Up to now, such drugs have mainly been used as a syringe. Now, a manufacturer provides data on a decrease pill.

Lean Left

No longer inject, but swallow: pharmaceutical manufacturers work on tablets against obesity. Preliminary study data show: they work. However, apparently a little less effective than weight loss injections.

·Germany
Read Full Article

So far, the medications in the fight against obesity were only available as a syringe. Eli Lilly, a pharmaceutical company, has now published the first clinical data on the weight loss pill. Will the tablet revolutionize obesity treatment?

·Munich, Germany
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Thursday, August 7, 2025.
Sources are mostly out of (0)
News
For You
Search
BlindspotLocal